SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Renovo Plc. -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (35)12/13/2007 1:19:57 PM
From: keokalani'nui  Respond to of 40
 
Analysts now having serious doubts about whether co has dose nailed down. Effectiveness of a high dose, given twice 24 hrs apart looks aberrant vs other doses but co gushing about poss of greater efficacy. Bottom line, all doses seem to provide some benefit with SS. P2 breast trial looks to be big inflection point.



To: keokalani'nui who wrote (35)12/13/2007 3:27:04 PM
From: nigel bates  Read Replies (1) | Respond to of 40
 
Ouch.
>>I thought company gave a pretty good explanation why the protocol was flawed...<<
I guess that's one of the reasons for doing PII trials ?

The dosage thing worries me too.
...with 500ng given twice and 200ng given once or twice being the most efficacious doses...
Shouldn't they have it pinned down a little better by now ?

2007 hasn't been a great year for me so far...

:-)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News